Martine A Rothblatt, Director, Chairperson & CEO, on June 25, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,228,773. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1082554/000110657826000086/xslF345X05/primarydocument.xml
Robert P. Farrell, President, Communication and Computing, on June 23, 2026, sold 2,920 shares in TTM Technologies (TTMI) for $612,598. Following the Form 4 filing with the SEC, Farrell has control over a total of 16,486 common shares of the company, with 16,486 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1116942/000119312526283125/xslF345X05/ownership.xml
Daniel L. Boehle, Executive Vice President and CFO, on June 23, 2026, sold 6,341 shares in TTM Technologies (TTMI) for $1,330,307. Following the Form 4 filing with the SEC, Boehle has control over a total of 72,922 common shares of the company, with 72,922 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1116942/000119312526283127/xslF345X05/ownership.xml
Dale Martin Knecht, Senior Vice President, Information Technology, on June 23, 2026, sold 6,754 shares in TTM Technologies (TTMI) for $1,416,952. Following the Form 4 filing with the SEC, Knecht has control over a total of 68,350 common shares of the company, with 68,350 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1116942/000119312526283121/xslF345X05/ownership.xml